DUBLIN – The ongoing delay in appointing a new executive director to the Innovative Medicines Initiative (IMI), Europe’s €3.3 billion (US$2.1 billion) public-private partnership on drug research, shows no immediate signs of ending, while its interim director, EC official Irene Norstedt, has defended the initiative against a major media onslaught led by Germany’s influential current affairs magazine Der Spiegel.